Mustang Bio, Inc. (MBIO)

0.3501 -0.0096 (-2.67%) At close: 04:00PM EDT

Mustang Bio, Inc.

377 Plantation Street
1st Floor
Worcester, MA 01605
United States
781 652 4500
https://www.mustangbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 80

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael S. Weiss Esq.	Executive Chairman	60k	N/A	1966
Dr. Manuel Litchman M.D.	President, CEO & Director	480.79k	N/A	1954
Mr. James B. Murphy	Interim Chief Financial Officer	N/A	N/A	1957
Mr. Peter Carney	Controller & Interim Chief Accounting Officer	N/A	N/A	1987
Mr. Matthew Wein J.D.	VP & General Counsel	N/A	N/A	N/A
Ms. Debra Manning SPHR	Senior VP & Head of Human Resources	N/A	N/A	N/A
Ms. Lynn E. Bayless M.S.	VP & Head of Regulatory Affairs	N/A	N/A	N/A
Dr. Bruce Dezube M.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A
Mr. Greg Furrow M.S.	Chief Quality Officer	N/A	N/A	N/A
Mr. Richard Bodmer M.S.	Head of CMC Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Corporate governance

Mustang Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.